NCT07079579View on ClinicalTrials.gov

Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD Patients

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Renal Anemia in Non-dialysis Chronic Kidney Disease
Interventions
DRUG

Enarodustat 2mg

initial phase：2mg QD for 4 weeks subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks

DRUG

Enarodustat 3mg

initial phase：3mg QD for 4 weeks subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks

DRUG

Enarodustat 4mg

initial phase：4mg QD for 4 weeks subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks

Trial Locations (1)

Unknown

Chinese PLA General Hosptial, Beijing

All Listed Sponsors
lead

Shenzhen Salubris Pharmaceuticals Co., Ltd.

INDUSTRY